Literature DB >> 29458954

Irreversible Electroporation in Hepatopancreaticobiliary Tumours.

A H Ruarus1, L G P H Vroomen2, R S Puijk2, H J Scheffer2, B M Zonderhuis3, G Kazemier3, M P van den Tol3, F H Berger4, M R Meijerink2.   

Abstract

Hepatopancreaticobiliary tumours are often diagnosed at an advanced disease stage, in which encasement or invasion of local biliary or vascular structures has already occurred. Irreversible electroporation (IRE) is an image-guided tumour ablation technique that induces cell death by exposing the tumour to high-voltage electrical pulses. The cellular membrane is disrupted, while sparing the extracellular matrix of critical tubular structures. The preservation of tissue integrity makes IRE an attractive treatment option for tumours in the vicinity of vital structures such as splanchnic blood vessels and major bile ducts. This article reviews current data and discusses future trends of IRE for hepatopancreaticobiliary tumours.
Copyright © 2017 Canadian Association of Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IRE; Irreversible electroporation; Liver neoplasms; Pancreatic neoplasms; Perihilar cholangiocarcinoma

Mesh:

Year:  2018        PMID: 29458954     DOI: 10.1016/j.carj.2017.10.005

Source DB:  PubMed          Journal:  Can Assoc Radiol J        ISSN: 0846-5371            Impact factor:   2.248


  7 in total

1.  Irreversible electroporation for hepatic tumors.

Authors:  Maurizio Pompili; Giampiero Francica
Journal:  J Ultrasound       Date:  2019-03-06

2.  Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy.

Authors:  Maria Paola Belfiore; Alfonso Reginelli; Nicola Maggialetti; Mattia Carbone; Sabrina Giovine; Antonella Laporta; Fabrizio Urraro; Valerio Nardone; Roberta Grassi; Salvatore Cappabianca; Luca Brunese
Journal:  Med Oncol       Date:  2020-04-09       Impact factor: 3.064

3.  A new intrasurgical technique to safely and reproducibly induce partial unilateral urinary obstruction and renal scarring in a Rat Model.

Authors:  Laurien G P H Vroomen; Nirmal Thampi John; Masashi Fuijmori; Arjun Sivaraman; Diane Felsen; Govindarajan Srimathveeravalli
Journal:  Int Urol Nephrol       Date:  2020-03-02       Impact factor: 2.370

Review 4.  Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?

Authors:  Yifan Wang; Mario Strazzabosco; David C Madoff
Journal:  Curr Oncol Rep       Date:  2022-10-18       Impact factor: 5.945

5.  High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity.

Authors:  Veronica M Ringel-Scaia; Natalie Beitel-White; Melvin F Lorenzo; Rebecca M Brock; Kathleen E Huie; Sheryl Coutermarsh-Ott; Kristin Eden; Dylan K McDaniel; Scott S Verbridge; John H Rossmeisl; Kenneth J Oestreich; Rafael V Davalos; Irving C Allen
Journal:  EBioMedicine       Date:  2019-05-23       Impact factor: 8.143

6.  Recurrent Colorectal Liver Metastases in the Liver Remnant After Major Liver Surgery-IRE as a Salvage Local Treatment When Resection and Thermal Ablation are Unsuitable.

Authors:  Lea Hitpass; Martina Distelmaier; Ulf P Neumann; Wenzel Schöning; Peter Isfort; Sebastian Keil; Christiane K Kuhl; Philipp Bruners; Alexandra Barabasch
Journal:  Cardiovasc Intervent Radiol       Date:  2021-11-10       Impact factor: 2.740

Review 7.  Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3-5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis.

Authors:  Sanne Nieuwenhuizen; Madelon Dijkstra; Robbert S Puijk; Bart Geboers; Alette H Ruarus; Evelien A Schouten; Karin Nielsen; Jan J J de Vries; Anna M E Bruynzeel; Hester J Scheffer; M Petrousjka van den Tol; Cornelis J A Haasbeek; Martijn R Meijerink
Journal:  Curr Oncol Rep       Date:  2022-03-17       Impact factor: 5.945

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.